Last reviewed · How we verify

NCT05789368

Efficacy Testing of VeCollal Products

Completed NA Last updated 9 November 2023
What this trial tests

NA trial testing Placebo sachet in Skin Condition in 90 participants. Completed in 28 June 2023.

Timeline
6 February 2023
Primary endpoint
30 April 2023
28 June 2023

Quick facts

Lead sponsorTCI Co., Ltd.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeother
Enrollment90
Start date6 February 2023
Primary completion30 April 2023
Estimated completion28 June 2023
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

TCI Co., Ltd. — full company profile →

Who can join

20 and older, any sex, with Skin Condition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess VeCollal formula on skin condition improvement

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Clinical Measurement of Transepidermal Water Loss.
    Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148

Verify or expand the search:

Other recruiting trials for Skin Condition

Currently open trials in the same condition.

Other TCI Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05789368.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing